From devices that count steps to devices that inform daily decisions
For years, Apple has been quietly repositioning its watch not as a timepiece or a fitness trinket, but as a window into the body's deeper rhythms. Evidence now suggests the Apple Watch 8, expected around 2022, may include blood sugar monitoring through a partnership with sensor specialist Rockley Photonics — a development that could meaningfully shift how millions of people, particularly those living with diabetes, relate to their own health. It is a reminder that the most consequential technologies often arrive not with fanfare, but through the patient accumulation of quiet investments.
- Apple's financial relationship with Rockley Photonics — where it accounts for the majority of the sensor firm's revenue — signals a commitment far too large to be exploratory.
- Glucose monitoring has been the most persistent and credible rumor in Apple Watch history, and SEC filings now give that speculation a paper trail.
- For diabetics and metabolically curious users alike, continuous blood sugar data on the wrist would represent a genuine leap beyond step-counting and heart rate alerts.
- Whether blood pressure and alcohol monitoring will accompany glucose tracking at launch remains unresolved, and Apple's methodical approach to health features suggests a phased rollout is likely.
- Regulatory approval looms as the critical unknown — any glucose feature must meet medical accuracy standards before it can reach consumers' wrists.
Apple has been building quietly toward a major expansion of its health ambitions. SEC filings reviewed by The Telegraph reveal that the company is Rockley Photonics' largest customer, a relationship that has driven the majority of the sensor maker's revenue for two years. Rockley specializes in optical sensors capable of measuring blood sugar, blood pressure, and alcohol levels — and its CEO has confirmed the technology will appear in consumer products starting in 2022. The evidence points strongly toward the Apple Watch 8.
Adding glucose monitoring would mark a meaningful evolution for the device. The Apple Watch already tracks heart rate, ECG patterns, and blood oxygen, but metabolic health has remained out of reach. Blood sugar data would be most immediately valuable to people managing diabetes, who monitor their levels throughout the day — but the appeal extends to anyone curious about how food, exercise, and stress affect their body in real time.
What Apple will actually launch remains uncertain. Glucose monitoring appears to be the most developed application, while blood pressure and alcohol tracking are possible but less confirmed. Apple tends to introduce health features carefully, validating them thoroughly before release, so a phased approach would fit its pattern. Regulatory approval will also be essential — accuracy standards for glucose monitoring are not merely technical benchmarks but medical requirements.
The Rockley partnership hints at ambitions beyond the watch itself, though the wrist remains the most natural first home for this technology. After a decade of health-focused acquisitions and platform building, adding glucose monitoring would be Apple's most consequential step yet into the territory where consumer technology and medical care begin to overlap.
Apple has been quietly building toward a significant expansion of its smartwatch health capabilities. According to SEC filings reviewed by The Telegraph, the company is Rockley Photonics' largest customer—a relationship that accounts for the majority of the sensor maker's revenue over the past two years. Rockley specializes in optical sensors designed to measure blood sugar, blood pressure, and alcohol levels, and the company's CEO has stated that its technology will appear in consumer products starting in 2022.
The timing and financial relationship point strongly toward the Apple Watch 8, even though earlier rumors suggested the feature might arrive as soon as the Watch 7. An Apple Watch with glucose monitoring would represent a meaningful step forward in the company's long-running effort to position the device as a serious health instrument rather than merely a fitness tracker. The watch already monitors heart rate, ECG patterns, and blood oxygen levels—adding glucose tracking would extend that reach into metabolic health, a domain that has grown increasingly important to consumers and health systems alike.
Glucose monitoring holds particular value for people living with diabetes, who must track their blood sugar levels throughout the day to manage their condition effectively. But the appeal extends beyond that population. Anyone interested in understanding how their body responds to food, exercise, and stress might find continuous glucose data useful. It's the kind of feature that could shift how people think about their wearables—from devices that count steps to devices that inform daily decisions about health.
What remains uncertain is whether Apple will integrate all three of Rockley's sensor capabilities into the Watch 8, or focus on glucose alone. Blood sugar monitoring has been the subject of persistent rumors and appears to be the most developed application. Blood pressure and alcohol monitoring are possibilities, but less certain. The company tends to introduce health features methodically, validating them thoroughly before launch, so a phased approach would not be surprising.
The partnership with Rockley also suggests Apple is thinking beyond the watch itself. Optical sensors of this type could eventually appear in other wearables or devices, though the watch remains the most logical first home for the technology. Apple has invested heavily in health sensors over the past decade, acquiring companies like Beats and building out its health app ecosystem. Adding glucose monitoring would be consistent with that trajectory, though it would also represent a step into territory where accuracy and regulatory approval matter enormously. The company will need to ensure any glucose monitoring feature meets medical standards before it reaches consumers.
Notable Quotes
Rockley Photonics CEO claimed the company's technology would be in consumer products from 2022— Rockley Photonics leadership
The Hearth Conversation Another angle on the story
Why would Apple care so much about blood sugar monitoring specifically? It seems like a niche health concern.
It's not niche at all—diabetes affects hundreds of millions of people worldwide. But more broadly, Apple sees the watch as a gateway to understanding your body's metabolic state. That's valuable whether you have diabetes or you're just curious about how your body works.
So Rockley Photonics is basically betting its entire business on Apple buying their sensors?
Essentially, yes. Apple accounts for most of their revenue, which is both a huge opportunity and a huge risk. If Apple decides to go a different direction or develop its own sensors, Rockley's in trouble.
When would this actually show up in a watch I could buy?
The CEO said 2022, which would align with the Watch 8. But Apple doesn't always move as fast as suppliers hope. There could be delays for validation or regulatory approval.
Would it actually work? Can you measure blood sugar through the skin without drawing blood?
That's the whole innovation—Rockley's optical sensors are designed to do exactly that. Whether they're accurate enough for real medical use is the open question. Apple will need to prove that before launching.
What if they only put glucose monitoring in and skip the alcohol tracking?
That's most likely. Glucose has been rumored for years and has clear medical value. Alcohol monitoring is more novel and less obviously useful. Apple tends to launch features one at a time, not all at once.